絞り込み

16530

広告

大飯原発訴訟 住民側が上告断念 敗訴確定へ

福井県にある大飯原子力発電所3号機と4号機について、住民らが関西電力に運転しないよう求めた裁判で、住民側は、17日、最高裁判所に上告しない方針を明らかにしました...

  1. 西日本豪雨の災害ごみ、中川環境相「広域処...
  2. ジェームズ・ウェッブ宇宙望遠鏡、今年2度...
  3. 版画・彫刻家の浜田知明さん死去 戦争テー...
  4. 俳優の生田悦子さん死去 (NHK)

ニュース一覧

Once versus twice daily direct oral anticoagulants in non-valvular atrial fibrillation.

著者 Ageno W , Beyer-Westendorf J , Rubboli A
Expert Opin Pharmacother.2017 Aug 08 ; ():.
この記事をPubMed上で見るPubMedで表示
この記事をGoogle翻訳上で見る Google翻訳で開く

スターを付ける スターを付ける     (170view , 0users)

Full Text Sources

Medical

Introduction Direct oral anticoagulants (DOACs) have emerged as alternatives to vitamin K antagonists for the prevention of stroke in patients with non-valvular atrial fibrillation (NVAF). Four DOACs: dabigatran, rivaroxaban, apixaban and edoxaban, are currently available. In the absence of head-to-head clinical comparisons of DOACs, dosing regimen may influence drug choice. Areas covered Edoxaban and rivaroxaban are administered once daily, dabigatran and apixaban twice daily. The selection of these dosage regimens is largely based on studies for the prevention or treatment of venous thromboembolism or acute coronary syndrome. Edoxaban is the only DOAC in which once and twice-daily regimens were compared in patients with NVAF; bleeding rates were higher in the twice-daily groups. Once-daily versus twice-daily regimens have a number of practical implications. Missing a once-daily dose would have a greater impact on anticoagulation. Some real world and retrospective studies found that a once-daily dosing regimen leads to better adherence and persistence to therapy, an important consideration for maintaining optimum anticoagulation. However, other studies have not found increased adherence among once daily regimens. Expert opinion Prescription of DOACs should be tailored to the individual patient and dosing regimen is only one of the variables that should be taken into account.
PMID: 28786696 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード